Medtech bleeds corporate venture cash
Overall venture investment in the sector remains steady, but the big strategics back off.
Delfi aims for a cheaper liquid biopsy
With a fresh $225m in the bank, Delfi works towards a cut-price, next-generation lung cancer screen.
Medtech venture backers go in early
A sudden increase in seed and series A funding bodes well for the year ahead.